CD markers variations in chronic lymphocytic leukemia: New insights into prognosis.

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most commonly occurring adult leukemias that is associated with clonal accumulation of mature apoptosis-resistant B-cells in bone marrow, peripheral blood, and specific tissues. Different pathogenesis factors can contribute to the aggression of the clinical course in this disease. Cytogenetic abnormalities and surface biomarkers of neoplastic CLL cells can be effective in the outcome of CLL, and the examination of changing CD markers expressions in the progression of CLL can be related to the prognosis of this disease. Changing expression levels of CD markers on lymphocytes and other cells in CLL patients can play a role in the aggressive clinical outcomes such as organomegaly, immunodeficiency, and advanced disease stages through their interaction with CLL microenvironment. Given the involvement of CD markers in the pathogenesis of CLL, it can be stated that recognizing the expression changes of CD markers in the cells involved in CLL can be a proper approach to evaluate prognosis among these patients.

• Authors: Tina Vosoughi, Marziye Bagheri, Mehran Hosseinzadeh, Ali Ehsanpour, Nader Davari, Najmaldin Saki
• Journal: Journal of cellular physiology (J Cell Physiol) Vol. 234 Issue 11 Pg. 19420-19439 (11 2019) ISSN: 1097-4652 [Electronic] United States
• PMID: 31049958 (Publication Type: Journal Article, Review)
• Copyright: © 2019 Wiley Periodicals, Inc.

Chemical References

• Antigens, CD
• Biomarkers, Tumor

Topics

• Antigens, CD (genetics)
• Apoptosis (genetics)
• B-Lymphocytes (metabolism, pathology)
• Biomarkers, Tumor (genetics)
• Clonal Evolution (genetics)
• Gene Expression Regulation, Leukemic (genetics)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (genetics, metabolism, pathology)
• Lymphocytes (metabolism)
• Prognosis
• Tumor Microenvironment (genetics)